Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ Lenz, E Van Cutsem, S Khambata-Ford… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …
被引用次数：642 相关文章

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ Lenz, E Van Cutsem… - Journal of …, 2006 - providence.elsevierpure.com
Purpose: This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …

[引用][C] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ LENZ, E VAN CUTSEM… - Journal of clinical …, 2006 - pascal-francis.inist.fr
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma
refractory to irinotecan, oxaliplatin, and fluoropyrimidines CNRS Inist Pascal-Francis CNRS …

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

HJ Lenz, E Van Cutsem, S Khambata-Ford… - Journal of Clinical …, 2006 - europepmc.org
Purpose This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ Lenz, E Van Cutsem… - Journal of clinical …, 2006 - pubmed.ncbi.nlm.nih.gov
Purpose This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …

[引用][C] MULTICENTER PHASE II AND TRANSLATIONAL STUDY OF CETUXIMAB IN METASTATIC COLORECTAL CARCINOMA REFRACTORY TO IRINOTECAN …

HJ LENZ, E VAN CUTSEM - 2006 - sid.ir

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ Lenz, E Van Cutsem… - Journal of …, 2006 - utsouthwestern.elsevierpure.com
Purpose: This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

HJ Lenz, E Van Cutsem, S Khambata-Ford… - Journal of Clinical …, 2006 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> This multicenter study evaluated the
antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal …

[引用][C] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

L HJ - J Clin Oncol, 2006 - cir.nii.ac.jp
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma
refractory to irinotecan, oxaliplatin, and fluoropyrimidines | CiNii Research CiNii 国立情報学 …

[引用][C] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

HJ LENZ, E VAN CUTSEM… - Journal of …, 2006 - American Society of Clinical …